Valeant Pharmaceuticals, a multinational specialty pharmaceutical company, has appointed Philip Loberg, the company’s former senior vice president (SVP) and corporate controller, has been named to the role of interim chief financial officer (CFO). He replaces former CFO Peggy Mulligan, who has elected to resign in order to pursue other interests. The company has initiated a search to identify a permanent replacement.
Loberg joined Valeant in 2000 as treasurer and was appointed CFO of North America in 2006. In 2007, he was appointed to his most recent role and has been responsible for the upgrading and retooling of the global finance department following restructurings and the disposition of non-performing assets. In addition, Loberg simplified and streamlined the SEC compliance and reporting process and was instrumental in the integration of multiple new businesses throughout the global enterprise.
Prior to joining Valeant, Loberg was the vice president, controller at Calcomp Technology, a subsidiary of Lockheed Martin Corporation, and was acting CFO early in his tenure. Loberg graduated with a BSc degree from the University of Southern California and completed his certified public accountant (CPA) exam in 1984.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.